Michael Farrell compensation by year
RESMED Summary Compensation Table · all 11 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $845,000 | $890,160 | $934,154 | $967,490 | $1,020,810 | $1,050,000 | $1,080,608 | $1,128,211 | $1,168,987 | $1,214,150 | $1,272,895 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $5,500,000 | $4,500,000 | $5,100,000 | $5,250,000 | $5,775,000 | $7,700,000 | $9,000,000 | $8,249,986 | $8,400,057 | $8,775,059 | $9,749,468 |
| Option awards | — | $1,500,000 | $1,700,000 | $1,750,000 | $1,925,000 | — | — | $2,749,989 | $2,800,025 | $2,925,007 | $3,249,907 |
| Non-equity incentive | $1,079,716 | $1,038,941 | $1,247,188 | $1,469,381 | $1,610,617 | $1,603,000 | $1,349,578 | $1,510,264 | $1,613,032 | $1,646,743 | $1,738,857 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $73,646 | $204,295 | $100,862 | $198,229 | $98,323 | $36,315 | $229,024 | $230,191 | $138,728 | $113,584 | $190,522 |
| Total | $7,498,362 | $8,133,396 | $9,082,204 | $9,635,100 | $10,429,750 | $10,389,315 | $11,659,210 | $13,868,641 | $14,120,829 | $14,674,543 | $16,201,649 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RESMED INC DEF 14A filed October 1, 2026, accession 0000943819-26-000080, and prior-year filings. Open the filing on EDGAR.
How this page was built: the RESMED INC filed document, accession 0000943819-26-000080. Every figure is read from that document and cited to the page and table it appears in. Filed October 1, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 24,588 | $4,791,709 | — |
| PSU | 16,913 | $3,296,005 | — |
| RSU | 14,617 | $2,848,561 | — |
| PSU | 13,547 | $2,640,039 | — |
| PSU | 6,167 | $1,201,825 | — |
| PSU | 5,483 | $1,068,527 | — |
| PSU | 5,222 | $1,017,663 | — |
| PSU | 4,727 | $921,198 | — |
| RSU | 4,098 | $798,618 | — |
| Option | 33,288 | — | $250.52 |
| Option | 22,024 | — | $249.56 |
| Option | 18,490 | — | $148.90 |
Per the Outstanding Equity Awards at Fiscal Year-End table in RESMED INC's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2025 proxy (filed October 1, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-07 | Exercise or conversion | 10b5-1 | 4,991 | $146.34 | 484,794 |
| 2026-10-07 | Sale | 10b5-1 | 4,991 | $226.33 | 479,803 |
| 2026-10-07 | Exercise or conversion derivative | 10b5-1 | 4,991 | $0.00 | 4,993 |
| 2026-08-14 | Grant or award | — | 13,547 | $0.00 | 479,803 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments RESMED discloses, by trigger · FY2026| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control, no termination | $0 | $8,939,473 | $0 | $8,939,473 |
| Change in control and involuntary termination | $7,865,000 | $6,338,771 | $69,410 | $14,340,190 |
| Disability | $0 | $21,678,165 | $1,173,031 | $22,851,196 |
| Death | $0 | $21,678,165 | $500,000 | $22,178,165 |
| Involuntary termination without cause | $0 | $5,832,525 | $0 | $5,832,525 |
Per the Potential Payments Upon Termination or Change in Control table in RESMED INC's FY2026 proxy. Estimates as the company printed them; a dash means it printed no figure.
RESMED’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Michael Farrell · this page | Chairman of the Board and Chief Executive Officer | $14,674,543 |
| Justin Leong | Chief Product Officer | $3,911,441 |
| Bobby Ghoshal | Chief Commercial Officer, Residential Care Software | $3,652,455 |
| Brett Sandercock | Chief Financial Officer | $3,572,010 |
| Michael Rider | Global General Counsel and Secretary | $2,289,122 |
Board service
RESMED board · FY2021–FY2026How this board is paid
Company policy: RESMED pays directors a $75,000 cash retainer and $260,000 in RSUs/Options. As stated in RESMED's FY2026 proxy.
The full RESMED compensation record
free company briefThis page is one person within RESMED's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the RESMED proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RESMED's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RESMED's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RMD
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.